Published on December 31, 2024 at 05:45.
9 mins. reading
The stock market has a tenacious memory. For some businesses, this can be cruel. The Swiss market thus preserves the traces of courses which, if they were transposed to clinical terrain, would amount to a coma, or even brain death. Companies listed in full force, supported by investors, before being abandoned, with no hope of getting back on track. For different reasons: change of era, technological breakthrough, industrial risk, objective impossible to achieve. The action then remains glued to the floor, year after year. Weighing only a fraction of their former value.
We have selected five case studies, whose valuation fell by more than 95% of their initial value at the time of the IPO. Five companies that have had glorious times, all classified as flagships of the Swiss economy in their respective fields at a given moment in their history: gene therapy with Geneva-based Addex, Montreux-based Airesis and sports equipment, Basel biotech Evolva and all-purpose yeasts, Leclanché from Yverdon and energy storage, Bernese Meyer Burger and smart solar.
Want to read all of our articles?
For CHF 29.- per month, enjoy unlimited access to our articles, without obligation!
I subscribe
Good reasons to subscribe to Le Temps:
- Unlimited access to all content available on the website.
- Unlimited access to all content available on the mobile application
- Sharing plan of 5 articles per month
- Consultation of the digital version of the newspaper from 10 p.m. the day before
- Access to supplements and T, the Temps magazine, in e-paper format
- Access to a set of exclusive benefits reserved for subscribers
Already have an account?
Log in
Business
